Abstract
Multiple endocrine neoplasia type 2A (MEN 2A) is a dominantly inherited cancer syndrome, which involves the triad of MTC, pheochromocytoma, and hyperparathyridism. Missense mutations in one of six cysteine codons in the extracellular cysteine-rich domain of the RET proto-oncogene predispose to this disease. These mutations cause ligand-independent constitutive activation of the tyrosine kinase receptor by the formation of disulfide-bonded homodimers. We examined a different type of mutation, which results in an additional cysteine in the cysteine rich domain. A duplication of 9 bp in the first case resulted in an insertion of three amino acids between codon 633 and 634. In the second case a 12 bp duplication in exon 11 results in four additional amino acids between codon 634 and 635. Here we demonstrate that an additional cysteine causes a ligand independent dimerization of the RET receptor in transfected NIH3T3 cells, which results in an activation of the intracellular tyrosine kinase.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Avantaggiato V, Dathan NA, Grieco M, Fabien N, Lazzaro D, Fusco A, Simeone A and Santoro M. . 1994 Cell Growth Differ. 5: 305–311.
Baloh RH, Tansey MG, Golden JP, Creedon DJ, Heuckeroth RO, Keck CL, Zimonjic DB, Popescu NC, Johnson EM and Milbrandt J. . 1997 Neuron 18: 793–802.
Berndt I, Reuter M, Saller B, Frank-Raue K, Groth P, Grußendorf M, Raue F, Ritter MM and Höppner W. . 1998 J. Clin. Endocr. Metab. 83: 770–774.
Bongarzone I, Vigano E, Alberti L, Mondellini P, Uggeri M, Pasini B, Borrello MG and Pierotti MA. . 1999 Oncogene 34: 4833–4838.
Borrello MG, Pelicci G, Arighi E, De Filipps L, Bongarzone I, Rizetti MG, Pellici PG and Pierotti MA. . 1994 Oncogene 9: 1661–1668.
Borrello MG, Alberti L, Arighi E, Bongarzone I, Battistini C, Bardelli A, Pasini B, Piutti C, Rizetti MG, Mondellini P, Radice MT and Pierotti MA. . 1996 Mol. Cell Biol. 16: 2151–2163.
Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P and Wells Jr SA. . 1993 Hum. Mol. Genet. 2: 851–856.
Durbec P, Marcos-Gutierrez CV, Kilkenny M, Grigoriou M, Wartiowaara K, Suvanto P, Smith D, Ponder B, Constantini F, Saarma M, Sariola H and Pachnis V. . 1996 Nature 381: 789–793.
Fattoruso O, Quadro L, Libroia A, Verga U, Lupoli G, Cascone E and Colantuoni V. . 1998 Hum. Mutat (Suppl 1) 167–171.
Höppner W and Ritter MM. . 1997 Hum. Mol. Genet. 6: 587–590.
Höppner W, Dralle H and Brabant G. . 1998 Hum. Mutat. (Suppl 1) 128–130.
Jing S, Wen D, Yu Y, Holst LP, Luo Y, Fang M, Tamir R, Antonio L, Hu Z, Cupples R, Louis JC, Hu S, Altrock BW and Fox GM. . 1996 Cell 85: 1113–1124.
Milbrand J, Sauvage FJ, Fahrner TJ, Baloh RH, Leitner ML, Tansey MG, Lampe PA, Heuckeroth RO, Kotzbauer PT, Simburger KS, Golden JP, Davies JP, Vejsada R, Kato AC, Hynes M, Sherman D, Nishimura M, Wang LC, Vandlen R, Moffat B, Klein RD, Poulsen K, Gray C, Garces A, Henderson CE, Phillips HS and Johnson EM. . 1998 Neuron 20: 245–253.
Mulligan LM, Kwock JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, Ponder MA, Telenius H, Tunnacliffe A and Ponder BAJ. . 1993 Nature 363: 458–460.
Nakamura T, Ishizaka Y, Nagao M, Hara M and Ishikawa T. . 1994 J. Pathol. 172: 255–260.
Pachnis V, Mankoo B and Constantini F. . 1993 Development 199: 1005–1017.
Romeo G, Ronchetto P, Luo Y, Barone V, Seri M, Ceccherini I, Pasini B, Bocciardi R, Lerone M, Kaariainen H and Martucciello G. . 1994 Nature 367: 377–378.
Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M, Fusco A, Veccio G, Matoskova B, Kraus MH and Di Fiore PP. . 1995 Science 267: 381–383.
Treanor JJS, Goodman L, De Sauvage F, Stone DM, Poulsen KT, Beck CD, Gray C, Armanini MP, Pollock RA, Hefti F, Phillips HS, Goddard A, Moore MW, Buj Bello A, Davies AM, Asai N, Takahashi M, Vandlen R, Henderson CE and Rosentthal A. . 1996 Nature 382: 80–83.
Acknowledgements
We are grateful to M Santoro and A Fusco for making the cDNA of the RET short isoform available to us. We thank James Olcese, Ulrike Klein and Natalia Schlabritz for critical reading of the manuscript. The technical assistance of Monika Kistler and the groups of HU Häring (Tübingen) and H Klein (Lübeck) is gratefully acknowledged. This work was supported by Forum Schilddrüse and the Deutsche Forschungsgemeinschaft (Graduiertenkolleg 336).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arlt, D., Baur, B., Wagner, B. et al. A novel type of mutation in the cysteine rich domain of the RET receptor causes ligand independent activation. Oncogene 19, 3445–3448 (2000). https://doi.org/10.1038/sj.onc.1203688
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203688
Keywords
This article is cited by
-
Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies
Nature Communications (2018)
-
Skewed mutational spectrum of RET proto-oncogene Exon10 in Iranian patients with medullary thyroid carcinoma
Tumor Biology (2015)
-
Plot protein: visualization of mutations
Journal of Clinical Bioinformatics (2013)
-
A newly identified RET proto-oncogene polymorphism is found in a high number of endocrine tumor patients
Human Genetics (2005)